S&P 500 gains on promising Covid-19 vaccine data, more stimulus hopes

Topics S&P 500 | Dow Jones | Lockdown

The S&P 500 edged higher on Monday as promising data across a range of Covid-19 vaccine candidates and hopes of more stimulus helped overcome fears around the extent of the economic damage from a surge in domestic infections.   US drugmaker Pfizer and German biotech firm BioNTech reported additional data from their experimental Covid-19 vaccine that showed it was safe and induced an immune response in patients.

Pfizer's shares rose 1.5%.   In the United Kingdom, data from AstraZeneca's experimental Covid-19 vaccine.....

This article is no longer available in our repository.

There could be multiple reasons for this.